This release has been authorised by the directors of Immuron Limited. Steven Lydeamore Chief Executive Officer ...

Jennifer B. Brooke Valerin, Jacob Thomas, J. Eva E. Selfridge, Madison Conces, Devalingam Mahalingam, Michael Cecchini, Elena G. Chiorean, Oana Danciu, Kyechin Chen, Ana Paula G. Cugnetti, Judith ...

The elritercept Phase 3 RENEW clinical trial (NCT06499285) is a global, randomized, double-blind, placebo-controlled trial in adults with transfusion-dependent anemia with very low, low, and ...

Separately, BioStem remains actively engaged in its Form 10 filing process and will provide additional updates on its planned Nasdaq uplisting during its second quarter 2025 earnings call.

Castle earns recognition as a national Healthcare Industry Top Workplace, an Arizona Top Workplace and receives five Top Workplaces Culture Excellence awards ...

Top Workplaces Industry awards celebrate organizations that have built people-first workplace cultures within their sector. The award marks them as an employer of choice for those seeking employment ...

ATLANTA, July 17, 2025 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that the company will release its second quarter results before the market open ...

Webcast and Conference Call to Be Held Tuesday, July 29, 2025, at 8:30 a.m. ET ...

When paired with oral legal peptides focused on recovery and muscle support, this stack becomes a dual-threat system: fat burning from one side, lean muscle retention from the other. Athletes report ...

Reconciling invoices and payments in clinical research has long been a fragmented, time-consuming, and error-prone task. Sites often use multiple siloed systems to manage invoices, while Sponsors and ...

WAYNE, Pa., July 17, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its second quarter financial results and provide an operational update at 8:00 a.m ...

“Rob and Seth are great additions to the Board of Directors. I look forward to working with them, and John in his new role, to create value for Harvard Bioscience’s shareholders. On behalf of the ...